Mechanistic insights into folic acid-dependent vascular protection: Dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: A novel HPLC-based fluorescent assay for DHFR activity

Journal of Molecular and Cellular Cardiology

Volumn 47, Issue 6, 2009, Pages 752-760

  Gao, Ling ^a   Chalupsky, Karel ^a   Stefani, Enrico ^a   Cai, Hua ^a  

^a Cardiovascular Research Laboratories   (United States)

Author keywords

Angiotensin II (Ang II); Dihydrofolate reductase (DHFR); Endothelial nitric oxide synthase (eNOS); Folic acid (FA); Nitric oxide (NO radical dot ); Tetrahydrofolic acid (THF)

Indexed keywords

ANGIOTENSIN II; DIHYDROFOLATE REDUCTASE; FOLIC ACID; NITRIC OXIDE; TETRAHYDROBIOPTERIN; TETRAHYDROFOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; CARDIOVASCULAR SYSTEM; CELL PROTECTION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANGIOTENSIN II; ANIMALS; BIOLOGICAL ASSAY; BIOLOGICAL AVAILABILITY; BUFFERS; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIETARY SUPPLEMENTS; ENDOTHELIAL CELLS; FLUORESCENCE; FOLIC ACID; INFUSION PUMPS; MICE; NITRIC OXIDE; OXIDANTS; PROTECTIVE AGENTS; REPRODUCIBILITY OF RESULTS; STRESS, PHYSIOLOGICAL; SUPEROXIDES; TETRAHYDROFOLATE DEHYDROGENASE; TETRAHYDROFOLATES; UP-REGULATION;

MUS;

EID: 70350610765     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.07.025     Document Type: Article

References (40)

1. Chivu C.M., Tulchinsky T.H., Soares-Weiser K., Braunstein R., and Brezis M. A systematic review of interventions to increase awareness, knowledge, and folic acid consumption before and during pregnancy. Am. J. Health Promot. 22 (2008) 237-245
2. Taparia S., Gelineau-van Waes J., Rosenquist T.H., and Finnell R.H. Importance of folate-homocysteine homeostasis during early embryonic development. Clin. Chem. Lab. Med. 45 (2007) 1717-1727
3. Maron B.A., and Loscalzo J. The treatment of Hyperhomocysteinemia. Annu. Rev. Med. (2008)
4. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 56 (1969) 111-128
5. McCully K.S. Homocysteine, vitamins, and vascular disease prevention. Am. J. Clin. Nutr. 86 (2007) 1563S-1568S
6. Welch G.N., and Loscalzo J. Homocysteine and atherothrombosis. N. Engl. J. Med. 338 (1998) 1042-1050
7. Loscalzo J. Key references: homocysteine and atherothrombotic vascular disease. J. Thromb. Thrombolysis 9 (2000) 125-126
8. Yap S., Boers G.H., Wilcken B., Wilcken D.E., Brenton D.P., Lee P.J., et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 2080-2085
9. Wilcken B., and Turner B. Homocystinuria. Reduced folate levels during pyridoxine treatment. Arch. Dis. Child. 48 (1973) 58-62
10. Wilcken D.E., and Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J. Clin. Invest. 57 (1976) 1079-1082
11. Weiss N., Heydrick S., Zhang Y.Y., Bierl C., Cap A., and Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 34-41
12. Weiss N., Heydrick S.J., Postea O., Keller C., Keaney Jr. J.F., and Loscalzo J. Influence of hyperhomocysteinemia on the cellular redox state-impact on homocysteine-induced endothelial dysfunction. Clin. Chem. Lab. Med. 41 (2003) 1455-1461
13. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N. Engl. J. Med. 354 (2006) 1629-1632
14. Jamison R.L., Hartigan P., Kaufman J.S., Goldfarb D.S., Warren S.R., Guarino P.D., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298 (2007) 1163-1170
15. Ray J.G., Kearon C., Yi Q., Sheridan P., and Lonn E. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann. Intern. Med. 146 (2007) 761-767
16. Spence J.D., Bang H., Chambless L.E., and Stampfer M.J. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke 36 (2005) 2404-2409
17. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 354 (2006) 1567-1577
18. Baigent C., and Clarke R. B vitamins for the prevention of vascular disease: insufficient evidence to justify treatment. JAMA 298 (2007) 1212-1214
19. Wang X., Qin X., Demirtas H., Li J., Mao G., Huo Y., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369 (2007) 1876-1882
20. Bazzano L.A., Reynolds K., Holder K.N., and He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 296 (2006) 2720-2726
21. Wald D.S., Wald N.J., Morris J.K., and Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 333 (2006) 1114-1117
22. Moens A.L., Vrints C.J., Claeys M.J., Timmermans J.P., Champion H.C., and Kass D.A. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. Am. J. Physiol., Heart Circ. Physiol. 294 (2008) H1971-H1977
23. Chalupsky K., and Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9056-9061
24. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87 (2000) 840-844
25. Oak J.H., and Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 56 (2007) 118-126
26. Seujange Y., Eiam-Ong S., and Tirawatnapong T. Role of angiotensin II on dihydrofolate reductase, GTP-cyclohydrolase 1 and nitric oxide synthase expressions in renal ischemia-reperfusion. Am. J. Nephrol. 28 (2008) 692-700
27. Ren J., Li H., Prior B.M., and Yang H.T. Angiotensin converting enzyme inhibition enhances collateral artery remodeling in rats with femoral artery occlusion. Am. J. Med. Sci. 335 (2008) 177-187
28. Gao L., Pung Y.F., Zhang J., Chen P., Wang T., Li M., et al. Sepiapterin reductase regulation of endothelial tetrahydrobiopterin and nitric oxide bioavailability. Am. J. Physiol., Heart Circ. Physiol. 297 (2009) H331-H339
29. Bauer M., Suppmann S., Meyer M., Hesslinger C., Gasser T., Widmer H.R., et al. Glial cell line-derived neurotrophic factor up-regulates GTP-cyclohydrolase I activity and tetrahydrobiopterin levels in primary dopaminergic neurones. J. Neurochem. 82 (2002) 1300-1310
30. Lu W., Li H., Zhang Y., and Ang C.Y. Rapid method for the determination of total 5-methyltetrahydrofolate in blood by liquid chromatography with fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 766 (2002) 331-337
31. Antoniades C., Shirodaria C., Warrick N., Cai S., de Bono J., Lee J., et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114 (2006) 1193-1201
32. Kalmbach R.D., Choumenkovitch S.F., Troen A.P., Jacques P.F., D'Agostino R., and Selhub J. A 19-base pair deletion polymorphism in dihydrofolate reductase is associated with increased unmetabolized folic acid in plasma and decreased red blood cell folate. J. Nutr. 138 (2008) 2323-2327
33. Aiso K., Nozaki T., Shimoda M., and Kokue E. Assay of dihydrofolate reductase activity by monitoring tetrahydrofolate using high-performance liquid chromatography with electrochemical detection. Anal. Biochem. 272 (1999) 143-148
34. Kaufman B.T., and Kemerer V.F. Purification and characterization of beef liver dihydrofolate reductase. Arch. Biochem. Biophys. 172 (1976) 289-300
35. Webber S., and Whiteley J.M. Comparative activity of rat liver dihydrofolate reductase with 7,8-dihydrofolate and other 7,8-dihydropteridines. Arch. Biochem. Biophys. 236 (1985) 681-690
36. Cai H., Griendling K.K., and Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 24 (2003) 471-478
37. Doshi S.N., McDowell I.F., Moat S.J., Lang D., Newcombe R.G., Kredan M.B., et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide?. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1196-1202
38. Shirodaria C., Antoniades C., Lee J., Jackson C.E., Robson M.D., Francis J.M., et al. Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation 115 (2007) 2262-2270
39. Chambers J.C., Ueland P.M., Obeid O.A., Wrigley J., Refsum H., and Kooner J.S. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 102 (2000) 2479-2483
40. Bellamy M.F., McDowell I.F., and Lewis M.J. Folic acid in endothelial function in familial hypercholesterolemia. Circulation 102 (2000) E92